Sexual activity to boost brain power of the elderly

June 23, 2017 – According to a new study involving 73 people between 50 and 83 years of age, just published in The Journals of Gerontology, Series B: Psychological and Social Sciences, more frequent sexual activity can boost brain power (i.e., intellectual and mental abilities) in older adults. In simple tests,

Read more ›

Share
Posted in Genetic Background, In The Press, New Research, Thasso Post, Theragenomic Medicine
Tags: , , , , , ,

Genetic background of insomnia: At least partially

June 20, 2017 – Insomnia is one of the most common complaint people have about their health. In contrast to common belief and often assumed by the affected sufferers, however, insomnia seems not to be just all in the patients head. A large genome wide association study (GWAS), an international

Read more ›

Share
Posted in Genetic Background, Genetic Predisposition, New Research, Thasso Post, Theragenomic Medicine
Tags: , , , , , ,

Development of a patient education video about pharmacogenetics

June 16, 2017 – Patient education in pharmacogenetics, the central component of theragenomic and personalized medicine and individualized drug safety is an important issue. Not only needs the individual patient to understand what pharmacogenetics, or more precisely, pharmacogenetic testing can do for him in the process of selection of the

Read more ›

Share
Posted in Companion Test, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Pharmacogenetics, Targeted Therapy, Thasso Post, Theragenomic Medicine
Tags: , , , , ,

Biomarker-guided Larotrectinib for all cancer types?

June 09, 2017 –  It’s only a couple of days that the American Food & Drug Administration (FDA) approved for the first time a cancer treatment for any solid tumor, irrespective of the tumor’s original location, as long as the targeted tumor is carrying a specific genetic feature (i.e., a specific biomarker). Thus, biomarkers

Read more ›

Share
Posted in Genetic Background, Genetic Predisposition, New Research, On The Horizon, Personalized Medicine, Targeted Therapy, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , , , ,

First cancer treatment for any solid tumor with MSI-H or dMMR approved

May 24, 2917 – The American Food & Drug Administration (FDA) just approved a major extension of the clinical indications for Pembrolizumab (Keytruda). For the first time,  a cancer treatment has been approved for any solid tumor, irrespective of the tumor’s original location, as long as the targeted tumor is carrying

Read more ›

Share
Posted in Genetic Background, New Indication Approval, Personalized Medicine, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , , ,

Theragenomics: Ivacaftor (Kalydeco) in the CFTR mutation-based treatment of cystic fibrosis (CF)

May 18, 2017 – Ivacaftor (Kalydeco) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are carriers one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or R117H. In contrast,

Read more ›

Share
Posted in Clinical Development, Genetic Background, New Indication Approval, Personalized Medicine, Regulatory Announcement, Thasso Post, Theragenomic Medicine
Tags: , , , , , , ,

Motivation and dangers of sharing personal genetic data in the open space

18 May 2017 – According to a paper just published in PLOS One, research team from the University of Zurich found that individuals who agree to openly share their direct-to-consumer (DTC) genetic testing data are apparently most interested in learning more about themselves, followed closely by an interest in advancing medical

Read more ›

Share
Posted in Genetic Background, New Research, Personalized Medicine, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , ,

Risk of leg and foot amputations under Canagliflozin (Invokana, Invokamet)

May 17, 2017 – Following up on an earlier Drug Safety Communication from May 2016 and based on new data from two large clinical trials, the American Food & Drug Administration (FDA) has concluded that the type 2 diabetes medicines Canagliflozin (Invokana), Canagliflozin/Metformin (Invokamet),  and Canagliflozin/Metformin (Invokamet XR) cause an

Read more ›

Share
Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , ,

Populations of African descent: New trait loci for hypertension

May 14, 2017 – Hypertension is a leading cause of global disease, mortality, and disability. Individuals of African descent suffer a disproportionate burden of hypertension and its complications. To date, there has been little information on the possible genetic background (i.e., genetic susceptibility) of hypertension in individuals of African descent. In

Read more ›

Share
Posted in Allelic Variant, Genetic Background, Genetic Predisposition, Genetic Susceptibility, New Research, Personalized Medicine, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , , ,

Lifeomics: Epigenetic DNA methylation-based life insurance?

Mai 07, 2017 – Genetics- and/or genomics-based approaches are penetrating every single aspect of human life. In contrast to the term theragenomics (therapy decisions with the help of  genetic/genomic information obtaineble from the patient concerned), we may coin the term lifeomics referring to decisions being taken concerning the daily life

Read more ›

Share
Posted in Genetic Background, In The Press, New Research, On The Horizon, Thasso Post, Theragenomic Medicine
Tags: , , , , ,

thasso: conditions

thasso post magazine

View my Flipboard Magazine.

follow thasso

Facebooktwittergoogle_pluslinkedinrssyoutubeby feather

subscribe to thasso

By signing up, you agree to our Terms of Service and Privacy Policy.

thasso: categories

thasso: archives

thasso: tweets

thasso chat / comments

You must be a registered user to participate in this chat.